NEWS
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
LAUSANNE, Switzerland and SAN DIEGO – July 15, 2024 – HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in … Read more
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics July 9, 2024 Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today … Read more
Tiesse: “La nuova frontiera di crescita sono le tlc satellitari”
Vincenzo Luciano Lucrezia, chief operating officer della società italiana specializzata in router e apparati di rete: “Grazie all’alleanza con Cysec offriamo valore aggiunto”. Il numero uno della cybercompany elvetica Patrick Trinkler: “Puntiamo allo sviluppo dello space internet che connetterà miliardi di persone” Antonello Salerno “Il comparto delle telecomunicazioni satellitari potrebbe essere una grande occasione, per l’Italia e … Read more
STALICLA publishes on identification of first autism subgroup and matching treatment
May 8, 2024 Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in … Read more
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant)
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder May 2, 2024 Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company’s drug-drug interaction (DDI) study of STP7 (Mavoglurant), an … Read more
Loi spatiale de l’UE : un fonctionnaire de la Commission européenne dévoile les aspects cyber de la législation
Type de contenu: Actualités Concernant la durabilité, le « niveau d’ambition [de la loi] sera assez faible », a averti M. de la Brosse, ajoutant qu’il n’existe actuellement aucune méthodologie pour calculer des effets de l’activité spatiale sur l’environnement. [Gorodenkoff / Shutterstock] Euractiv fait partie de The Trust Project >>> Langues : English | Deutsch Imprimer Un représentant de la Commission … Read more
Appointment will propel STALICLA’s mission to develop their late-stage clinical assets for precision brain disease treatment.
STALICLA Appoints Dr. Thomas Blaettler, MD Date: Friday, Jan. 19, 2024 GENEVA–(BUSINESS WIRE)– STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer. Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights … Read more
« Au sein de l’Union européenne, il n’existe pour l’instant aucun cadre juridique harmonisé relatif aux activités spatiales »
Mathieu Bailly, vice-président de Cysec, plaide, dans une tribune au « Monde », en faveur d’une réglementation européenne obligatoire en matière de sécurité spatiale pour faire face aux risques sécuritaires, géopolitiques et économiques. Vous pouvez partager un article en cliquant sur les icônes de partage en haut à droite de celui-ci.La reproduction totale ou partielle d’un article, … Read more
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more
